文献速递自身炎症与 IgG4 相关病

生物制剂治疗斯蒂尔病的疗效与安全性:随机对照试验的系统评价与网络Meta分析

Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该系统评价与网络Meta分析纳入9项随机对照试验共430例斯蒂尔病患者,评估阿那白滞素、卡那奴单抗、利纳西普和托珠单抗的疗效与安全性。所有生物制剂相比安慰剂均与更高的ACR50缓解几率相关,生物制剂与严重不良事件无统计学显著关联。根据SUCRA排序,阿那白滞素在ACR50缓解和严重不良事件发生方面是最有效且最安全的选择。

要点

  • 所有生物制剂相比安慰剂均与更高的ACR50缓解几率相关。
  • 生物制剂与严重不良事件之间无统计学显著关联。
  • SUCRA排序显示阿那白滞素在疗效和安全性方面均居首位。

核心结论

  • 生物制剂在斯蒂尔病管理中能有效达到ACR缓解,并表现出低不良事件特征。
  • 这是首个评估生物制剂在儿童和成人斯蒂尔病患者中疗效与安全性的系统评价与Meta分析。

研究设计与样本

  • 系统评价与网络Meta分析,研究方案在PROSPERO注册(CRD42023450442)。
  • 检索MEDLINE、EMBASE和CENTRAL,从建库至2023年9月17日。
  • 纳入9项随机对照试验共430例斯蒂尔病患者,干预为安慰剂或生物制剂(阿那白滞素、卡那奴单抗、利纳西普或托珠单抗)。

主要发现

  • 所有生物制剂相比安慰剂均与更高的ACR50缓解几率相关。
  • 生物制剂与严重不良事件之间无统计学显著关联。
  • 多变量Meta分析未发现生物制剂之间的差异。
  • 根据SUCRA排序,阿那白滞素在ACR50缓解和严重不良事件发生方面是最有效且最安全的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Still's disease is a rare autoinflammatory disorder characterized by systemic inflammation, fever, rash and arthritis. The term 'Still's disease' covers the paediatric subtype systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), which affects adults. Biologic drugs, including the anti-IL-1 agents anakinra, canakinumab and rilonacept and the IL-6 antagonist tocilizumab, are used in the management of Still's disease. METHODS: We conducted a systematic review and network meta-analysis of randomized controlled trials, and the study protocol was registered in PROSPERO (CRD42023450442). MEDLINE, EMBASE and CENTRAL were screened from inception until 17 September 2023. We included patients with Still's disease who received placebo or biologic drugs: anakinra, canakinumab, rilonacept or tocilizumab. The primary efficacy and safety outcomes were achievement of ACR50 response and occurrence of serious adverse events, respectively. The interventions were ranked using rankograms and SUCRA values. RESULTS: Nine trials with 430 patients were included. All biologic drugs were associated with greater odds of ACR50 response compared with placebo. There was no statistically significant association between biologic drugs and serious adverse events. The multivariate meta-analysis found no difference between biologic drugs. As per SUCRA rankings, anakinra was the most effective and safe option with respect to ACR50 response and occurrence of serious adverse events. CONCLUSION: This is the first systematic review and meta-analysis to assess the efficacy and safety of biologic drugs in paediatric and adult patients with Still's disease. Biologic drugs were effective in achieving ACR response and demonstrated a low adverse event profile in the management of Still's disease.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kilic B, Ozturk A, Karup S, et al. Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2025. PMID: 38775654. doi:10.1093/rheumatology/keae295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。